Trastuzumab Biosimilar (HLX02), Pertuzumab Plus Chemotherapy in Patients with HER2-Positive Metastatic Breast Cancer after Progression of Trastuzumab: A Prospective, Phase II Study

Ruyan Zhang; Xiaoran Liu; Guohong Song; Yan Zhang; Huiping Li

doi:10.4143/crt.2023.1151

Articles

Page Path: HOME > Cancer Res Treat > Volume 56(3); 2024 > Article

Original Article Breast cancer Trastuzumab Biosimilar (HLX02), Pertuzumab Plus Chemotherapy in Patients with HER2-Positive Metastatic Breast Cancer after Progression of Trastuzumab: A Prospective, Phase II Study: Ruyan Zhang¹, Xiaoran Liu¹, Guohong Song¹, Yan Zhang², Huiping Li^1,; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2024;56(3):795-801.
DOI: https://doi.org/10.4143/crt.2023.1151
Published online: December 20, 2023

¹Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, China

²State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing, China

Correspondence: Huiping Li, Department of Breast Oncology, Peking University Cancer Hospital and Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China
Tel: 86-13811012595 Fax: 86-10-88196739 E-mail: huipingli2012@hotmail.com

• Received: October 20, 2023 • Accepted: December 19, 2023

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

4,044 Views
145 Download

prev next

Full Article

Download PDF

Abstract

Purpose
This study aims to evaluate the efficacy and safety of trastuzumab biosimilar (HLX02) in combination with pertuzumab and chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer (MBC) after progression of trastuzumab.
Materials and Methods
In this prospective, single-arm, phase II study, patients with HER2-positive MBC after progression of trastuzumab received pertuzuamb, HLX02, and chemotherapy in Beijing Cancer Hospital from March 2020 to December 2022. The primary endpoint was progression-free survival (PFS), and secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety. The study was registered with ClinicalTrials.gov (NCT05188495).
Results
A total of 45 patients were included in this study. Twelve patients (26.7%) were treated in second-line and 33 patients (73.3%) were in third-line and later setting. Eighty percent and 15.5% patients had previously received pyrotinib/lapatinib and T-DM1, respectively. With a median follow-up of 24.4 months (range, 1.2 to 43.9 months), the median PFS was 7.6 months (95% confidence interval, 4.3 to 10.9), OS was not reached, the ORR was 31.1%, and DCR was 91.1%. The treatment was well tolerated.
Conclusion
The combination of trastuzumab biosimilar HLX02, pertuzumab, and chemotherapy exhibited promising efficacy and a favorable safety profile as second- and beyond-line treatment in HER2-positive MBC.
Key words: Trastuzumab biosimilar, HLX02, Pertuzumab, Metastatic breast cancer, HER2-positive

Introduction

Trastuzumab-based targeted therapy has greatly improved the survival of human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer (MBC) in the past decades. CLEOPATRA study established the standard of first-line treatment of trastuzumab, pertuzumab combined with paclitaxel for HER2-positive MBC based on its significant overall survival (OS) advantage [1]. PUFFIN trial confirmed the survival benefit of dual anti-HER2 therapy in Chinese population [2].

The second-line treatment options for advanced breast cancer after progression of trastuzumab include antibody drug conjugates (ADC) like T-DM1, DS8201, and small molecule tyrosine kinase inhibitors (TKIs) including lapatinib, pyrotinib, tucatinib, and neratinib. However, not all people can afford ADCs due to expensive cost, and patients who used ADCs will also eventually experience disease progression. Up to now, there is no standard of care for third-line or later treatment [3-5].

Previous studies have shown that retaining trastuzumab in combination with other chemotherapy drugs after trastuzumab progression significantly prolongs OS compared to discontinuing trastuzumab [6-8]. However, whether the addition of pertuzumab to trastuzumab could achieve better efficacy in this population remains unclear. Trials evaluating the efficacy of dual anti-HER2 therapy with pertuzumab and trastuzumab in second- and beyond line setting are limited, and reported mixed conclusions [9-14]. Randomized phase III study PHEREXA reported that the addition of pertuzumab to trastuzumab plus capecitabine did not significantly improve progression-free survival (PFS) as second-line treatment, but an 8-month increase in median OS was observed [12]. Besides, randomized PRECIOUS study showed that pertuzumab retreatment in combination with trastuzumab and chemotherapy (TC) significantly improved PFS and showed a trend towards better OS than TC in patients previously treated with pertuzumab [10].

HLX02 (Zercepac) is the first manufactured trastuzumab biosimilar in China. It has been approved in China and some European countries based on its confirmed similar efficacy and safety in combination with chemotherapy compared with the reference drug in phase III study of first-line treatment for HER2-positive MBC. Nevertheless, data on whether HLX02 combined with pertuzumab and chemotherapy is safe and efficient in HER2-positive especially in trastuzumab pre-treated MBC patients is still lacking.

Therefore, we conducted this prospective study to evaluate the efficacy and safety of the trastuzumab biosimilar HLX02, pertuzumab plus chemotherapy (TPC) in patients with HER2-positive advanced breast cancer after trastuzumab progression. This study was approved by the Ethics Committee of Peking University Cancer Hospital (approval ID: 2020KT151) in Beijing, China, and was registered with ClinicalTrials.gov (NCT05188495).

Materials and Methods

1. Key eligibility criteria

Eligible patients aged 18years or older with histologically confirmed HER2-positive invasive breast cancer. HER2-positive status confirmed by immunohistochemistry 3+ and/or fluorescence in situ hybridization confirmed gene amplification (HER2/CEP17 ratio ≥ 2). Other criteria are as follows: (1) Patients with MBC previously treated with trastuzumab (during neo/adjuvant setting or metastatic setting) and have experienced disease progression while or after receiving trastuzumab-based therapy; (2) Measurable disease as defined per Response Evaluation Criteria in Solid Tumor v.1.1 criteria. Patients with only central nervous system diseases are not suitable for inclusion; (3) Eastern Cooperative Oncology Group performance status 0-2; (4) Adequate organ and bone marrow function; (5) Left ventricular ejection fraction (LVEF) ≥ 50%, determined by echocardiography; (6) Patients who have received pertuzumab for metastatic diseases are excluded (if used during adjuvant or neo-adjuvant, the time from the last medication to recurrence or metastasis should be more than 12 months); (7) Untreated symptomatic progressive brain metastases occurred within 30 days before randomization are excluded.

2. Trial design

This is a prospective single-arm, single-center, phase II clinical trial. Eligible patients were assigned at baseline to receive trastuzumab (HLX02), pertuzumab, and chemotherapy based on physician’s choice. Trastuzumab (HLX02) was given intravenously as an 8 mg/kg loading dose followed by 6 mg/kg maintenance doses every 3weeks. Pertuzumab was given intravenously as an 840mg loading dose followed by 420 mg maintenance doses every 3 weeks. Physician’s choice of chemotherapy agents including taxels (docetaxel, paclitaxel, and nab-paclitaxel), gemcitabine, eribulin, capecitabine, or vinorelbine monotherapy. The administration approach referred to the recommendations in the 2020 Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Breast Cancer.

3. Assessment

Tumor assessment was carried out every 6 weeks with a computed tomography scan of the chest with or without a scan of the abdomen (depends on the presence of abdominal metastases), and if the disease had not progressed after 6 months, the investigator decided whether to continue chemotherapy. Trastuzumab and pertuzumab continued to be applied until the disease progressed or toxicity became intolerable, hormone receptor–positive patients were allowed to receive endocrine therapy as maintenance therapy. Responses were evaluated using Response Evaluation Criteria in Solid Tumor 1.1 criteria.

The primary endpoint was PFS, secondary endpoints included OS, objective response rate (ORR), disease control rate (DCR), and safety. PFS was calculated from the time of first administration to the time of disease progression or death, OS was calculated from the time of first administration to the time of death due to any cause. ORR was defined as the proportion of patients with measurable disease whose best overall response was evaluated as either complete remission (CR) or partial remission (PR). DCR was defined as the proportion of patients who achieved CR, PR, and stable disease (SD). LVEF was monitored at baseline and every three months with an echocardiogram during targeted therapy. Adverse events (AEs) were graded according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events, ver. 5.0 (NCI CTCAE 5.0).

4. Statistical analysis

The sample size was calculated using one-sample log-rank test based on the primary endpoint of PFS. According to the data of previous studies (TH3RESA and SOPHIA trial), we assume that PFS shorter than 4.5 months is not ideal, and not shorter than 7.5 months is promising, with a target hazard ratio of 0.60, two-sided alpha level of 5%, and power of 80%, the enrollment time and follow-up time were both 12 months, a Weibull distribution shape parameter of k=1, estimate 39 evaluable subjects, the expected number of events during the study is 31. Considering the actual possible shedding (calculated by 15%), a total of 45 patients was required in this study.

Kaplan-Meier method was used to analyze PFS, OS, and inter-group comparisons were performed using the log-rank test. SPSS ver. 26.0 (IBM Corp., Armonk, NY) was used for all statistical analyses, and p < 0.05 was considered statistically significant.

Results

1. Patient characteristics

A total of 45 patients were enrolled in this study from March 2020 to December 2022. The median age was 56 years (range, 35 to 70 years). The baseline characteristics of the population are provided in Table 1.

Among them, 24 patients (53.3%) had hormone receptor–positive disease, 38 patients (84.4%) had visceral metastases, the median number of previous lines of treatment for metastatic disease was two with a range of one to six, 12 patients (26.7%) were treated in second line and 33 patients (73.3%) were treated in third-line and later setting. The occurrence of relapse was observed in nine patients either during or within 12 months after the completion of adjuvant trastuzumab therapy. Thirty-six patients (80%) had previously received pyrotinib or lapatinib, and seven patients (15.5%) had previously received both T-DM1 and TKIs. Taxanes and vinorelbine were the most common chemotherapy agents combined. Notably, granulocyte colony-stimulating factor (G-CSF) was used prophylactically after chemotherapy in 25 patients (55.6%).

2. Efficacy

At a median follow-up period of 24.4 months (range, 1.2 to 43.9 months), 35 patients (77.8%) in 45 patients had PFS events. The median PFS was 7.6 months (95% confidence interval [CI], 4.3 to 10.9) (Fig. 1), OS was not reached due to short follow-up time. The subgroup analysis of PFS was conducted based on hormone receptor status, presence of liver metastasis, prior treatment line and combined chemotherapy regimen. No statistically significant differences were observed in the subgroup analysis for PFS (Table 2).

The 45 patients had the best clinical response as follows: 14 (31.1%) had a PR, 27 (60%) had SD, four patients (8.9%) had progressive disease, and no patients had CR. The ORR was 31.1%, DCR was 91.1% (Table 3).

3. Safety

The safety profile is summarized in Table 4. AEs of all grades shown had a frequency of 10% or higher. Most toxicities were grade 1–2 and manageable, including neutropenia (20 patients [44.4%]), anemia (nine [20.0%]), diarrhea (nine [20.0%]), alanine aminotransferase/aspartate aminotransferase elevation (eight [17.8%]), grade 3 or higher AEs were mainly neutropenia (three patients [6.7%]) which was considered to be associated with chemotherapy, not with trastuzumab and pertuzumab. No infusion related reaction and no clinical significant decline in LVEF was observed. Overall, the study regimen was generally well tolerated, exhibiting no unexpected toxicities.

Discussion

To our knowledge, this is the first study to evaluate the efficacy and safety of the trastuzumab biosimilar (HLX02) combined with pertuzumab as second line and beyond treatment in patients with advanced HER2-positive breast cancer after progression of trastuzumab. The median PFS was 7.6 months (95% CI, 4.3 to 10.9), which achieved its priori target promising outcome: 7.5 months. The study regimen was generally well tolerated, no clinical significant decline in LVEF was observed.

The chemotherapy regimens in our study included a variety of physician-selected drugs, most commonly taxanes and vinorelbine, the PFS was 7.6 months, and no significant differences were observed between taxane and non-taxane regimen groups. Furthermore, 73.3% of patients had received at least two lines of therapy, 85% of patients had received pyrotinib, and 15% of patients had received T-DM1 before enrollment.

In the TH3RESA trial, which targeted the later-line population, the median number of previous treatment lines was four, and 100% of the patients were treated with lapatinib, median PFS for T-DM1 and physician’s choice were 6.2 months vs. 3.3 months (p < 0.0001) [15]. In SOPHIA study for margetuximab (M), 91% of the enrolled population had received T-DM1, 65.8% of the patients had received ≤ 2 previous lines of treatment in the metastatic setting, and the investigator-assessed median PFS was 5.7 months with M+chemotherapy vs. 4.4 months with H+ chemotherapy (hazard ratio, 0.70 [95% CI, 0.56 to 0.87]; p=0.001) [16]. Although we cannot compare our data directly with the data from previous studies, a median PFS of 7.6 months is also favorable and promising.

Notably, prior treatment with pertuzumab in the metastatic phase was not allowed in our study. In fact, pertuzumab was not available in China until 2019, and until now, medical insurance only covers the use of pertuzumab in the early stage, not in the metastatic phase, as a result, many patients were treated with single target therapy of trastuzumab in the first-line setting. In PRECIOUS study, median PFS was 5.3 months with TPC and 4.2 months with TC as third- or fourth-line therapy for patients with prior pertuzumab treatment (p=0.022) [10]. And another single-arm study reported a similar PFS of 5.5 months with gemcitabine, pertuzumab, and tratuzumab as second-line and beyond therapy after prior treatment with pertuzumab [8]. Without previous exposure of pertuzumab may contributed to the longer PFS in our study than in the two aforementioned studies. It was mentioned that the recently published PHILA study in China has shown that the first-line treatment with pyrotinib combined with trastuzumab and docetaxel has achieved a PFS of more than 2 years (24.3 months), which is longer than the PFS of THP in CLEOPATRA (18.7 months) [17]. Therefore, pyrotinib has been approved by the China Food and Drug Administration for the first-line treatment of HER2-positive MBC in April 2023. This will lead to new changes in the antiHER2 treatment landscape in China, and pertuzumab may lose its standard position in first-line treatment. Thus this study exploring the efficacy of pertuzumab in the posterior line of treatment has important realistic clinical implications in China.

In Destiny-Breast 03 trial, the median PFS of DS8201 in second-line therapy has reached 28 months [18], and Destiny-Breast 09 trial is ongoing to compare the first-line efficacy of DS8201 and TPC, if it can confirm that DS8201 is superior to the H+P dual-antiHER2 therapy in the first-line treatment, pertuzumab will lose its status as the standard of care in the first-line treatment in the worldwide and may only be used in the later-line treatment after T-DM1 and TKIs by then. Our study provides new data and evidence regarding the efficacy and safety of pertuzumab plus trastuzumab in the treatment of patients beyond the second-line setting.

Regarding to safety, grade 3 and higher AEs were mainly neutropenia, which was lower than reported in previous studies, due to prophylactic use of G-CSF in a significant number of patients. In contrast to other anti-HER2 drugs, most of which have a significant incidence of AE of special interest, such as thrombocytopenia with T-DM1 [15,19,20], diarrhea with TKIs [21-23], higher infusion-related reactions with margetuximab compared with trastuzumab (13.3% vs. 3.4%) [16], interstitial lung disease and gastrointestinal effects with DS8201 [18,24,25], the dual-targeted therapy of trastuzumab and pertuzumab had a lower incidence of perceived toxicity and was better tolerated.

The main limitations of this study are the single arm and single-center study design. Multi-center, and randomized controlled trials could be conducted in the future to address these limitations. Furthermore, the follow-up time was not long enough to allow for OS analysis, additional survival data will be reported with further enrollment and longer follow-up.

In conclusion, this study demonstrated promising efficacy and confirmed favorable safety profile of the combination of trastuzumab biosimilar HLX02, pertuzumab, and chemotherapy as second- and beyond-line treatment in HER2-positive MBC, these findings provide new evidence for use of dual-antibody therapy in late-line setting of HER2-positive MBC.

NOTES

Ethical Statement

This study was approved by the Ethics Committee of Peking University Cancer Hospital (Approval ID: 2020KT151), all the participants provided written informed consent.

Author Contributions

Conceived and designed the analysis: Zhang R, Li H.

Collected the data: Zhang R, Song G.

Contributed data or analysis tools: Zhang R, Liu X, Song G, Zhang Y.

Performed the analysis: Zhang R, Liu X, Zhang Y.

Wrote the paper: Zhang R, Li H.

Conflicts of Interest

Conflict of interest relevant to this article was not reported.

Acknowledgements

This work was supported by the WU JIEPING medical foundation (Grant number:320.6750.2020-20-37). We would like to thank all patients and the staff of Peking University Cancer Hospital who participated in our study.

Fig. 1.

Progression-free survival of 45 patients. CI, confidence interval; mPFS, median progression-free survival.

Table 1.

Baseline characteristics of 45 patients

Characteristic	No. (%) (n=45)
Age (yr), median (range)	56 (35-70)
ECOG performance status
0-1	40 (88.9)
2	5 (11.1)
Hormone receptor
Positive	24 (53.3)
Negative	21 (46.7)
Visceral disease involvement	38 (84.4)
Liver	23 (51.1)
Lung	25 (55.6)
Brain	5 (11.1)
Previous trastuzumab exposure
(Neo)adjuvant setting	17 (37.8)
De novo stage IV	11 (24.4)
Metastatic setting	30 (66.7)
Previous other anti-HER2 therapy for metastatic disease
TKI (pyrotinib or lapatinib)	36 (80.0)
T-DM1+TKI	7 (15.5)
Previous treatment line for metastatic disease, median (range)	2 (1-6)
1	12 (26.7)
2	18 (40.0)
≥ 3	15 (33.3)
Combined chemo-regimens
Taxanes	22 (48.9)
Nab-paclitaxel	17 (37.8)
Docetaxel	3 (6.7)
Paclitaxel	2 (4.4)
Vinorelbine	13 (28.9)
Capecitabine	4 (8.9)
Gemcitabine	4 (8.9)
Eribulin	2 (4.4)

ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor receptor 2; TKI, tyrosine kinase inhibitor.

Table 2.

PFS of subgroups for 45 patients

Subgroup	No. (events)	Median PFS (mo) (95% CI)	p-value
Hormone receptor
Negative	21 (15)	10.3 (6.1-14.5)	0.199
Positive	24 (20)	5.8 (4.0-7.5)
Liver metastasis
Yes	23 (18)	6.2 (4.0-8.4)	0.460
No	22 (17)	8.2 (6.0-10.4)
Prior treatment lines
1	12 (8)	6.2 (0-18.9)	0.492
≥ 2	33 (27)	7.6 (4.8-10.3)
Chemotherapy regimen
Taxanes	22 (17)	7.6 (3.1-12.1)	0.721
Non-taxanes	23 (18)	7.4 (4.5-10.3)

CI, confidence interval; PFS, progression-free survival.

Table 3.

Best overall response of 45 patients

Best overall response	No. (%) (n=45)
CR	0
PR	14 (31.1)
SD	27 (60.0)
PD	4 (8.9)
ORR (CR+PR)	14 (31.1)
DCR (CR+PR+SD)	41 (91.1)

CR, complete response; DCR, disease control rate; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease.

Table 4.

Adverse events of 45 patients

Adverse event	No. (%) (n=45)
Grade ≥ 3 adverse event	3 (6.7)
LVEF (< 50% or ≥ 15% reduction from baseline)	0
Infusion-related reaction	0
Most common adverse events^a)b)
Diarrhea	9 (20.0)/9 (20.0)/0
Neutropenia	20 (44.4)/17 (37.8)/3 (6.7)
Anemia	9 (20.0)/9 (20.0)/0
ALT/AST elevation	8 (17.8)/8 (17.8)/0

ALT, alanine aminotransferase; AST, aspartate aminotransferase; LVEF, left ventricular ejection fraction.

^a) Reported in ≥ 10% of patients,

^b) All grade/grade 1-2/grade 3-4.

REFERENCES

1. Swain SM, Kim SB, Cortes J, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14:461–71. Article PubMed PMC
2. Xu B, Li W, Zhang Q, Li Q, Wang X, Li H, et al. Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study. Breast Cancer Res Treat. 2023;197:503–13. Article PubMed PMC PDF
3. Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023;22:101–26. Article PubMed PMC PDF
4. Tapia M, Hernando C, Martinez MT, Burgues O, TebarSanchez C, Lameirinhas A, et al. Clinical impact of new treatment strategies for HER2-positive metastatic breast cancer patients with resistance to classical anti-HER therapies. Cancers (Basel). 2023;15:4522.Article PubMed PMC
5. Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andre F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31:1623–49. PubMed
6. Extra JM, Antoine EC, Vincent-Salomon A, Delozier T, Kerbrat P, Bethune-Volters A, et al. Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist. 2010;15:799–809. Article PubMed PMC PDF
7. von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, et al. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer. 2011;47:2273–81. Article PubMed
8. Iyengar NM, Smyth LM, Lake D, Gucalp A, Singh JC, Traina TA, et al. Efficacy and safety of gemcitabine with trastuzumab and pertuzumab after prior pertuzumab-based therapy among patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: a phase 2 clinical trial. JAMA Netw Open. 2019;2:e1916211Article PubMed PMC
9. Dang C, Iyengar N, Datko F, D’Andrea G, Theodoulou M, Dickler M, et al. Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2015;33:442–7. Article PubMed PMC
10. Yamamoto Y, Iwata H, Taira N, Masuda N, Takahashi M, Yoshinami T, et al. Pertuzumab retreatment for HER2-positive advanced breast cancer: a randomized, open-label phase III study (PRECIOUS). Cancer Sci. 2022;113:3169–79. Article PubMed PMC PDF
11. Yamamoto Y, Iwata H, Ueno T, Taira N, Kashiwaba M, Takahashi M, et al. A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study. Jpn J Clin Oncol. 2018;48:855–9. Article PubMed
12. Urruticoechea A, Rizwanullah M, Im SA, Sanchez Ruiz AC, Lang I, Tomasello G, et al. Final overall survival (OS) analysis of PHEREXA: a randomized phase III trial of trastuzumab (H) plus capecitabine (X) +/- pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) who experienced disease progression during or after H-based therapy. J Clin Oncol. 2018;36(15 Suppl):1013.
13. Urruticoechea A, Rizwanullah M, Im SA, Sanchez-Ruiz AC, Lang I, Tomasello G, et al. PHEREXA: a phase III study of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) for patients (pts) who progressed during/after one line of H-based therapy in the HER2-positive metastatic breast cancer (MBC) setting. J Clin Oncol. 2016;34(15 Suppl):504.Article
14. Qian Y, Peng Y, Zhou H, Zhang L, Yuan Y. Trastuzumab plus pertuzumab in combination with chemotherapy in metastatic HER2-positive breast cancer: a retrospective single-armed cohort study in China. Ann Transl Med. 2022;10:877.Article PubMed PMC
15. Krop IE, Kim SB, Gonzalez-Martin A, LoRusso PM, Ferrero JM, Smitt M, et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:689–99. Article PubMed
16. Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Musolino A, et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021;7:573–84. Article PubMed PMC
17. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial. BMJ. 2023;383:2665.Article PubMed PMC
18. Cortes J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386:1143–54. PubMed
19. Dieras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:732–42. Article PubMed PMC
20. Welslau M, Dieras V, Sohn JH, Hurvitz SA, Lalla D, Fang L, et al. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Cancer. 2014;120:642–51. Article PubMed
21. Xu B, Yan M, Ma F, Hu X, Feng J, Ouyang Q, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:351–60. Article PubMed
22. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–43. Article PubMed
23. Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥2 HER2-directed regimens: phase III NALA trial. J Clin Oncol. 2020;38:3138–49. PubMed PMC
24. Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610–21. PubMed
25. Iihara H, Shimokawa M, Bando H, Niwa Y, Mizuno Y, Kawaguchi Y, et al. Doublet or triplet antiemetic prophylaxis for nausea and vomiting induced by trastuzumab deruxtecan: an open-label, randomized, and multicenter exploratory phase 2 Study. J Cancer. 2023;14:2644–54. Article PubMed PMC

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Trastuzumab Biosimilar (HLX02), Pertuzumab Plus Chemotherapy in Patients with HER2-Positive Metastatic Breast Cancer after Progression of Trastuzumab: A Prospective, Phase II Study

Cancer Res Treat. 2024;56(3):795-801. Published online December 20, 2023

DOI: https://doi.org/10.4143/crt.2023.1151

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
NOTES
REFERENCES

Trastuzumab Biosimilar (HLX02), Pertuzumab Plus Chemotherapy in Patients with HER2-Positive Metastatic Breast Cancer after Progression of Trastuzumab: A Prospective, Phase II Study

Fig. 1. Progression-free survival of 45 patients. CI, confidence interval; mPFS, median progression-free survival.

Fig. 1.

Trastuzumab Biosimilar (HLX02), Pertuzumab Plus Chemotherapy in Patients with HER2-Positive Metastatic Breast Cancer after Progression of Trastuzumab: A Prospective, Phase II Study

Characteristic	No. (%) (n=45)
Age (yr), median (range)	56 (35-70)
ECOG performance status
0-1	40 (88.9)
2	5 (11.1)
Hormone receptor
Positive	24 (53.3)
Negative	21 (46.7)
Visceral disease involvement	38 (84.4)
Liver	23 (51.1)
Lung	25 (55.6)
Brain	5 (11.1)
Previous trastuzumab exposure
(Neo)adjuvant setting	17 (37.8)
De novo stage IV	11 (24.4)
Metastatic setting	30 (66.7)
Previous other anti-HER2 therapy for metastatic disease
TKI (pyrotinib or lapatinib)	36 (80.0)
T-DM1+TKI	7 (15.5)
Previous treatment line for metastatic disease, median (range)	2 (1-6)
1	12 (26.7)
2	18 (40.0)
≥ 3	15 (33.3)
Combined chemo-regimens
Taxanes	22 (48.9)
Nab-paclitaxel	17 (37.8)
Docetaxel	3 (6.7)
Paclitaxel	2 (4.4)
Vinorelbine	13 (28.9)
Capecitabine	4 (8.9)
Gemcitabine	4 (8.9)
Eribulin	2 (4.4)

Subgroup	No. (events)	Median PFS (mo) (95% CI)	p-value
Hormone receptor
Negative	21 (15)	10.3 (6.1-14.5)	0.199
Positive	24 (20)	5.8 (4.0-7.5)
Liver metastasis
Yes	23 (18)	6.2 (4.0-8.4)	0.460
No	22 (17)	8.2 (6.0-10.4)
Prior treatment lines
1	12 (8)	6.2 (0-18.9)	0.492
≥ 2	33 (27)	7.6 (4.8-10.3)
Chemotherapy regimen
Taxanes	22 (17)	7.6 (3.1-12.1)	0.721
Non-taxanes	23 (18)	7.4 (4.5-10.3)

Best overall response	No. (%) (n=45)
CR	0
PR	14 (31.1)
SD	27 (60.0)
PD	4 (8.9)
ORR (CR+PR)	14 (31.1)
DCR (CR+PR+SD)	41 (91.1)

Adverse event	No. (%) (n=45)
Grade ≥ 3 adverse event	3 (6.7)
LVEF (< 50% or ≥ 15% reduction from baseline)	0
Infusion-related reaction	0
Most common adverse events^a)b)
Diarrhea	9 (20.0)/9 (20.0)/0
Neutropenia	20 (44.4)/17 (37.8)/3 (6.7)
Anemia	9 (20.0)/9 (20.0)/0
ALT/AST elevation	8 (17.8)/8 (17.8)/0

Table 1. Baseline characteristics of 45 patients

ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor receptor 2; TKI, tyrosine kinase inhibitor.

Table 2. PFS of subgroups for 45 patients

CI, confidence interval; PFS, progression-free survival.

Table 3. Best overall response of 45 patients

CR, complete response; DCR, disease control rate; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease.

Table 4. Adverse events of 45 patients

ALT, alanine aminotransferase; AST, aspartate aminotransferase; LVEF, left ventricular ejection fraction.